Isolated decreased serum-immunoglobulin (Ig)M has been associated with severe and/or recurrent infections, atopy and autoimmunity. However, the reported high prevalence of clinical problems in IgM-deficient patients may reflect the skewed tertiary centre population studied so far. Also, many papers on IgM deficiency have included patients with more abnormalities than simply IgM-deficiency. We studied truly selective primary IgM deficiency according to the diagnostic criteria of the European Society for Immunodeficiencies (ESID) (true sIgMdef) by reviewing the literature (261 patients with primary decreased serum-IgM in 46 papers) and analysing retrospectively all patients with decreased serum-IgM in a large teaching hospital in 's-Hertogenbosch, the Netherlands [1 July 2005-23 March 2016; n 5 8049 IgM < 0Á4 g/l; n 5 2064 solitary (IgG1IgA normal/IgM < agematched reference)]. A total of 359 of 2064 (17%) cases from our cohort had primary isolated decreased serum-IgM, proven persistent in 45 of 359 (13%) cases; their medical charts were reviewed. Our main finding is that true sIgMdef is probably very rare. Only six of 261 (2%) literature cases and three of 45 (7%) cases from our cohort fulfilled the ESID criteria completely; 63 of 261 (24%) literature cases also had other immunological abnormalities and fulfilled the criteria for unclassified antibody deficiencies (unPAD) instead. The diagnosis was often uncertain (possible sIgMdef): data on IgG subclasses and/or vaccination responses were lacking in 192 of 261 (74%) literature cases and 42 of 45 (93%) cases from our cohort. Our results also illustrate the clinical challenge of determining the relevance of a serum sample with decreased IgM; a larger cohort of true sIgMdef patients is needed to explore fully its clinical consequences. The ESID online Registry would be a useful tool for this.
Introduction
Immunoglobulin (Ig)M deficiency is, on one hand, reported to be associated with a wide range of clinical presentations, including severe or recurrent infections, atopy, autoimmunity and malignancy [1] . On the other hand, there are doubts about its clinical significance [2] ; studies in healthy populations have shown that genetic polymorphisms as well as environmental factors may influence serum IgM levels [2, 3] . Previous studies on the clinical significance of IgM deficiency have been affected by selection bias towards 'disease' , as mostly symptomatic patients from tertiary centre cohorts have been described [4] [5] [6] .
The European Society for Immunodeficiencies (ESID) Registry defines primary selective IgM deficiency (sIgMdef) as a serum IgM level repeatedly below 2 standard deviations (s.d.) of normal with normal levels of serum IgA, IgG and IgG subclasses, normal vaccination responses, absence of T cell defects and absence of causative external factors (http:// www.esid.org). Many previously published papers that report on 'IgM deficiency' do not fulfil these criteria [7, 8] .
To facilitate a clear discussion, we define three categories in our study: (i) truly selective primary IgM deficiency (true sIgMdef) -the ESID criteria are completely fulfilled, which means that serum IgM levels are decreased repeatedly and IgG, IgA, IgG-subclasses and vaccination responses have been determined and were normal for age; we consider the absence of clinical signs suggesting a T cell defect sufficient; (ii) possible selective primary IgM deficiency (possible sIgMdef) -the diagnosis of true sIgMdef is uncertain, which means that the ESID criteria are not fulfilled completely, because data on IgG subclasses and/or vaccination responses are lacking; and (iii) unclassified primary antibody deficiency (unPAD) -other abnormalities in antibodies are also present: IgG-subclass deficiency, below-normal levels of IgG or IgA and/or impaired vaccination responses.
The aim of our study was to learn more about the clinical significance of true sIgMdef. Therefore, we first conducted a scoping review to identify all previously published patients with decreased serum IgM. Secondly, we analysed decreased serum IgM identified through the laboratory files of the Jeroen Bosch Hospital in 's-Hertogenbosch, the Netherlands, a large teaching hospital (secondary centre). Finally, we analysed whether these fulfilled the criteria for true sIgMdef.
Materials and methods

Literature search
The PubMed database was searched for papers concerning 'IgM deficiency' published until 10 May 2017 (no starting date). The search query was defined as {selective OR isolated} AND {IgM OR Immunoglobulin M} AND {defi-ciency OR low} AND {immunodeficiency syndromes}. We also screened the reference lists of papers identified by our search strategy and added those papers that reported about decreased serum IgM (snowball method). Our search strategy is described in detail in Supporting information, Fig.  S1 . We considered decreased serum IgM to be secondary in combination with the use of immunosuppressive agents, malignancy (e.g. clear cell sarcoma, promyelocytic leukaemia, multiple myeloma) or gastrointestinal loss (e.g. enteropathy through Crohn's or coeliac disease). Only papers that (also) contained patients with primary decreased serum IgM were included into the study. We analysed whether these patients fulfilled the criteria for true sIgMdef.
Our cohort
Patient selection. All serum immunoglobulin levels determined between 1 July 2005 and 23 March 2016, in the Jeroen Bosch Hospital (JBZ) in 's-Hertogenbosch, the Netherlands (encatchment area 350 000; 500 000 out-patient visits and 32 000 admissions per year), were obtained [n 5 38 149; 5342 (14%) samples from children and 32 509 (85%) samples from adults, missing age values in 298 samples]. Of these, all samples with serum IgM values < 0Á4 g/l were selected (n 5 8049, details in Supporting information, Fig. S2 ). Samples were excluded if serum IgM levels were normal according to age-matched reference values (these were all young children) [9] . To identify all patients with isolated decreased serum IgM, samples with decreased age-matched IgA and/or IgG values as well as follow-up samples of serum IgM were excluded. The medical charts were screened regarding patient history and medication use to exclude the samples from those patients in whom decreased serum IgM could be secondary (caused by external factors; for definition, see literature review above). Patients with cystic fibrosis (n 5 3) were excluded because their clinical symptoms would be difficult to interpret. Laboratory data of all primary cases were analysed to identify patients in whom serum IgM level was determined only once and in whom serum IgM level was determined repeatedly, but had normalized. Only the medical charts of patients with persistent decreased serum IgM levels were reviewed in detail; this patient group comprises both possible and true primary sIgMdef (for definitions, see Introduction). The Medical Ethical Committee Brabant approved the study.
Data collection. Data on demographics, clinical features, laboratory results and treatment, conclusions written by medical specialists and ICD-10 codes were derived from our electronic patient system. For clinical evaluation, we collected the type of medical specialist who discovered the decreased serum IgM, reason(s) for determining serum IgM and clinical problems that could be related to antibody deficiency. We considered the following clinical problems to be possibly related to antibody deficiency: infections, atopic and/or autoimmune manifestations, inflammation of the gastrointestinal tract, long-lasting fatigue, depression and malignancies. Pneumonia required confirmation by thoracic X-ray. Allergic diseases (allergic rhinoconjunctivitis, food allergy, allergic urticaria, allergic anaphylaxis) required confirmation by skin-prick testing or radioallergosorbent test (RAST). For immunological evaluation, we collected data on serum IgM, IgG and IgA levels and, if determined, data on IgG subclasses, T cell subsets and function, antibody responses to vaccinations, isohaemagglutinin levels, anti-nuclear antibodies (ANA) and specific serum IgE directed against inhalant allergens. For interpretation of serum immunoglobulins and lymphocyte subpopulations, age-matched reference values were used [10] . Because our laboratory cut-off for serum IgM levels is 0Á2 g/l, a value of < 0Á2 g/l was replaced by 0Á1 g/l for calculating mean serum IgM level (n 5 4). For interpretation of pneumococcal antibody responses, laboratory specific reference values were used [11] . The follow-up period was defined as the date of the first serum sample with decreased IgM until the date of data extraction. All patient data were encrypted and saved on a protected server using Research Manager software developed by Cloud9 Health Solutions (Deventer, the Netherlands).
Statistical analysis. Statistical analysis was performed using SPSS 
Results
Literature search
Supporting information, Table S1 provides an overview of the identified relevant literature. A total of 261 patients with primary decreased serum IgM were described in 46 papers; eight patients (two adults and six children) fulfilled the criteria for combined immunodeficiency and these were excluded. Only six of 261 patients (2Á3%, three adults and three children) fulfilled the ESID criteria completely for true sIgMdef; 63 of 261 (24Á1%; 44 adults and 19 children) fulfilled the criteria for unclassified antibody deficiency. In 192 of 261 patients (73Á6%, 164 adults and 28 children) the diagnosis was uncertain (possible sIgMdef), due to incomplete laboratory data ( Fig. 1) .
Clinical and laboratory features of the published adult and paediatric cases with true or possible sIgMdef are summarized in Tables 1 and 2 . More than two-thirds of both adults and children were male (57 of 85 adults, 67% versus 23 of 31 children, 74%). Many patients presented with infectious problems (30 of 62 adults, 48% versus 14 of 15 children, 93%). In three of 62 (5%) of the reported adults, decreased IgM was identified 'by accident' as part of laboratory evaluation for ischaemic heart disease, hypertension and visual disturbance. Thirteen of 62 (21%) of the reported adults and one of 15 (7%) children were asymptomatic; this boy was detected during family screening. Serum IgM values were reported in 86 adults and 14 children (mean 0Á23 g/l, range 0Á004-0Á45 g/l for adults versus mean 0Á18 g/l, range 0Á00-0Á36 g/l for children). Undetectable serum IgM levels were reported in two children [12, 13] and four adults [14] . Three adults and one baby were treated with intravenous immunoglobulin substitution (IVIG).
Our cross-sectional retrospective cohort
A total of 2064 patients with isolated decreased serum IgM were identified in the laboratory system of the JBZ (1 July 2005-23 March 2016): 2034 adults and 17 children aged 6-18 years (13 children < 6 years were excluded because the age-matched reference value was lower than the cut-off value of the test). The patient selection process is shown in detail in Supporting information, Fig. S2 ; 1685 of 2034 adults (83%) and seven of 17 (41%) children had secondary isolated decreased serum IgM; 349 of 2034 (17%) adults and 10 of 17 (59%) children had a primary form; of these, serum IgM levels were determined more than once in only 49 of 349 (14%) adults and three of 10 (30%) children. In seven of 49 (14%) of the adults the serum IgM level normalized, yielding persistent isolated decreased Clinical and laboratory features are described in Tables 2 (three children) and 3 (42 adults). The onset and duration of symptoms could not be determined accurately in the medical files; 24% of the adults and two of the three children were analysed for suspected potential immunodeficiency. The others were detected during analysis for other problems; however, 22% of these adults and one child had a history of symptoms that could be related to antibody deficiency (mainly infections). The majority (72%) of adults without such symptoms remained asymptomatic during follow-up; 28% developed symptoms that could be related to antibody deficiency. In none of the patients was a family history of immunodeficiency found in the medical charts. Only 7% (two adults and one child) fulfilled the ESID criteria completely for true sIgMdef.
The first serum IgM level in possible or true sIgMdef cases ranged from < 0Á2 to 0Á39 g/l (mean 0Á30 6 0Á84) in the adults and from 0Á28 to 0Á38 g/l (mean 0Á34 6 0Á05) in the children. First serum IgA levels were increased (> 4Á0 g/l) in seven adults (17%). Serum IgE levels were determined in six adults and one child (mean 133 6 182 U/ ml; range 5-410 U/ml); they were elevated (> 90 U/ml) in two adults. None of the patients were treated with IVIG or prophylactic antibiotics.
Discussion
We studied true sIgMdef (according to the ESID diagnostic criteria) by reviewing the literature and by analysing decreased serum IgM in our secondary hospital population. Our main finding is that true sIgMdef is probably very rare. Unfortunately, when a decreased serum IgM level is found, it is rarely analysed fully. In most cases in our cohort serum IgM levels were determined only once (86%). When proven persistently decreased, further immunological analysis is often not performed (data on IgG subclasses and/or vaccination responses were lacking in 74% of the literature cases and 93% of the cases in our cohort). Also, different criteria for 'selective IgM deficiency' are used in the literature; in a quarter of the cases, the deficiency is not 'selective' , other immunological abnormalities were present. Eight literature cases even showed clinical and/or laboratory signs fitting combined immunodeficiency; these should not be classified as a form of 'predominantly 'asymptomatic' and 'no' is that 'no' refers to patients who were screened for problems not related to antibody deficiency in contrast to asymptomatic patients, who had no clinical problems at all. ‡ Seventy patients were reported without specific age indications or exact IgM levels in this paper. § Clinical manifestations of patients were not described separately in this paper. Mean age at diagnosis of the whole group was 54 years; 11 males, 12 females. One patient was treated with intravenous Ig (IVIG) because of refractory asthma. ¶ Patient data were not described separately in this paper. Of the 20 described patients, 50% had also specific anti-polysaccharide antibody deficiency and fulfilled the criteria for 'unclassified antibody deficiency'. Therefore, these 10 patients were not included in this antibody deficiency'. Sixty-three (24%) literature cases fitted the ESID classification 'unclassified antibody deficiency'. These patients with concomitant defects in specific antibody production (SPAD) and/or IgG subclass deficiencies may be at risk of more severe and frequent infections, comparable to the increased number of lower respiratory tract infections and bronchiectasis in patients with IgA deficiency in combination with IgG subclass deficiency and/or SPAD [15] . Patients with recurrent and/or severe infections and decreased serum IgM levels in combination with SPAD have been described to benefit from immunoglobulin treatment [4, 16] . Routine determination of serum IgM is advised in many medical protocols, mainly for adults; we showed in our cohort that this leads to many incidental findings of decreased serum IgM. The relatively common finding of a low serum IgM level in, immunologically speaking, asymptomatic adults (see Table 3 ), often not followed by further evaluation, warrants re-evaluation of these medical protocols. In our cohort, secondary decreased serum IgM was five times more prevalent in adults and 2Á5 times more prevalent in children than the primary form. Hobbs [17] reported that secondary decreased IgM was 20 times more prevalent than the primary form in 1975. This may be explained by the fact that age-related reference values have changed over the years, as the sensitivity of the methods used to measure serum IgM increased (Hobbs et al. < 0Á47 g/l > 3 years, our cohort < 0Á21 g/l < 6 years, < 0Á13 g/l < 16 years and < 0Á40 g/l ! 16 years). In any case, the first reaction to finding a low IgM should be to exclude a secondary cause.
The fact that only a few incidental findings of decreased serum IgM were followed by further evaluation in our cohort suggests that the perceived medical problems were mild. Most of our incidentally diagnosed cases with true or possible sIgMdef did not have a history of symptoms related to antibody deficiency (76%), and that often remained to be the case during follow-up (72%) (conversely, 28% later developed symptoms that could be related to antibody deficiency). The higher prevalence of various associated diseases in the literature cases [1] is probably related to the fact that these patients had been referred to specialized allergy and immunology clinics [4] [5] [6] . The three paediatric patients from our cohort and 31 paediatric patients with true or possible selective primary IgM deficiency (sIgMdef) from the literature. *Patients were not described separately in this paper. Median age at diagnosis was 4Á2 years; 10 males, six females. CMV 5 cytomegalovirus; F 5 female; Ig 5 immunoglobulin; IVIG 5 intravenous immunoglobulin; M 5 male; n.a. 5 not applicable; n.r. 5 not reported; URTI 5 upper respiratory tract infection; RLS 5 Raynaud-like symptoms. Interestingly, possible or true sIgMdef was observed more frequently in males in our cohort. This parallels the observed male predominance in the literature. However, also among healthy controls low IgM levels are more common in males [18] [19] [20] [21] , and there are some reports of low serum IgM levels among fathers of patients [22, 23] . It would be of interest to investigate this gender difference further.
The limitation of our study is, of course, its retrospective design. We collected our cohort data from the medical files, which were not collected with a research purpose in mind. Therefore, we could not correct for environmental factors and genetic polymorphisms that may influence serum IgM levels [3] . However, although very interesting on a population basis, these factors are probably not very helpful in directing decisions regarding individual patient care in the doctor's consulting room.
In conclusion, our review of the literature and retrospective secondary centre cohort study on decreased serum IgM illustrate the challenge of determining the clinical significance of a serum sample with decreased IgM. The diagnosis could rarely be made with certainty, but truly selective primary IgM deficiency is probably very rare. Our strict definitions and thorough analysis of the available information have yielded the largest cohort study so far. However, a larger cohort of true sIgMdef patients is needed to fully explore the clinical consequences; the ESID online Registry would be a useful tool for this.
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